NGEN

About NervGen Pharma Corp. Common stock (NGEN) Stock

NervGen Pharma Corp. Common stock (NGEN) closed the 2026-09-16 session at $2.13, down 0.47% versus the previous close (-0.01). The stock opened at $2.16 and traded between $2.08 and $2.18 during that session. Session trading volume was 453K shares. The volume-weighted average price (VWAP) is $2.13.

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

NervGen Pharma Corp. Common stock has a market capitalization of $230.1 million. NGEN is listed on the XNAS exchange. The company employs approximately 9 people. The recorded listing date is 2019-03-25.

On this page you can find market NGEN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors.